The patients with RET+ NSCLC in our cohort, otherwise, shared similar patterns of metastases to those with ALK+ or ROS1+ NSCLC, including high frequencies of pleural and bone metastases and lymphangitic carcinomatosis (Table 3; Figure 1). The gene discussed is RET; the disease is non-small cell lung carcinoma.